

Supplemental Appendix

Supplemental Table 1: Page 2

Supplemental Figure S1: page 3

Supplemental Figure S2: page 4

Supplemental Figure S3: page 5

Supplemental Figure S4: page 6

Supplemental Figure S5: page 7


Supplemental Figure S6: page 8

Supplemental Figure S7: page 9

Supplemental Table 1. List of antibodies used for flow cytometry


<i>Antibody</i>	<i>Clone</i>	<i>Source</i>	<i>Catalog#</i>
Bcl-xL-PE	7B2.5	Abcam	ab26035
CD45.1-FITC	A20	BioLegend	110706
CD45.2-PE	104	BioLegend	109808
CD4-PECY7	RM4-5	BioLegend	100528
Foxp3-APC	FJK-16s	Invitrogen	17-5773-82
TNF α -PE	MP6-XT22	Invitrogen	12-7321-82
Ki67-APC-eF780	SolA15	Invitrogen	47-5698-82
CD69-PerCP-Cy5.5	H1.2F3	Tonbo	65-0691-U100

Supplemental Figures




Supplemental Figure 1

Supplemental Figure 1. (A) Representative flow contour plots showing cardiac TNFR1⁺CD4⁺ helper T-cells at 3 days post-MI or sham surgery, and (B) group quantitation for their frequency at 3 days (left) and 8 weeks (right) post-MI or sham surgery. (C) Group quantitation for frequency of TNFα⁺ cells and its MFI in CD4⁺TNFR1⁻ and CD4⁺TNFR1⁺ T cells in the spleens of HF mice. Data in (B) and (C) were analyzed using unpaired Student's t-test. *p<0.05, **p<0.01 and ***p<0.001 represent significance with respect to indicated groups.




Supplemental Figure 2

Supplemental Figure 2. **(A)** Quantitative data for different generations (G1-G5) that proliferated 1-5 times in the absence and presence of different concentration of anti-TNFR1 antibody. Data is shown from a representative experiment. **(B)** Fold change in the frequency (%) of CD69⁺CD4⁺ T-cells in proliferated T-cells treated with different concentrations of neutralizing anti-TNFR1 antibody. All experiments were repeated 4 times with 3-4 replicates in each experiment and fold change (*right*) calculated with respect to non-treated stimulated controls for each individual experiment is shown. Data in **(B)** were analyzed using one-way ANOVA and p-values were adjusted using FDR.




Supplemental Figure 3. Group quantitation for end-systolic and end-diastolic volumes (ESV and EDV), and ejection fraction (EF) of heart failure WT and TNFR1^{-/-} donor mice at the time of cell isolation. Data were analyzed using unpaired Student's t-test.



Supplemental Figure 4


Supplemental Figure 4. (A) Adoptively transferred HF-activated WT or TNFR1^{-/-} donor CD45.2⁺CD4⁺ T-cells in the mediastinal (*left*) and inguinal lymph nodes (*right*) of CD45.1 recipient mice at 14 weeks post-transfer. (B) CD44^{hi}CD69⁺ activated T-cells among adoptively transferred CD45.2⁺CD4⁺ T-cells derived from HF WT or TNFR1^{-/-} mice in the spleens of CD45.1 recipient mice at 14 weeks post-transfer. Data in (A), and (B) were analyzed using unpaired Student's t-test. *p<0.05, and **p<0.01 represent significance with respect to indicated groups.



Supplemental Figure 5


Supplemental Figure 5. (A) Heart rate of recipient CD45.1 mice at baseline (before injection) and at 14 weeks post-adoptive transfer of CD45.2⁺ T-cells isolated either from the WT or TNFR1^{-/-} sham or HF mice. (B) Group quantitation for end-systolic and end-diastolic volumes (ESV and EDV), and ejection fraction (EF) of CD45.1⁺ recipient mice before the adoptive-transfer (at baseline) of HF-activated CD45.2⁺CD4⁺ T-cells isolated either from WT or TNFR1^{-/-} mice. Data were analyzed using two-way ANOVA and p-values were adjusted using FDR.

Recipient Hearts: Donor Derived Cells



Supplemental Figure 6

Supplemental Figure 6. Group quantitation for frequency (%) of **(A)** CD45.2⁺CD4⁺ CD69⁺, **(B)** CD45.2⁺CD4⁺ IFN γ ⁺ Th1 and **(C)** CD45.2⁺CD4⁺ IL-17⁺ Th17 T-cells among total donor-derived CD45.2⁺CD4⁺ T-cells in the hearts of CD45.1 recipient mice injected either with sham or HF T-cells isolated either from WT or TNFR1^{-/-} mice. Study was repeated 2-times (n=2-5 in each study) and data from one experiment are shown. Data were analyzed using two-way ANOVA and p-values were adjusted using FDR. *p<0.05, **p<0.01 and ***p<0.001 represent significance with respect to indicated groups.



Supplemental Figure 7

Supplemental Figure 7. **(A)** cell counts of donor-derived CD45.2⁺CD4⁺ Ki67⁺ T-cells in the mediastinal and **(B)** inguinal lymph-nodes of recipient CD45.1 mice injected with HF T-cells isolated either from WT or TNFR1^{-/-} mice. Study was repeated 2-times (n=2-5 in each study) and data from one experiment are shown. Data were analyzed using unpaired Student's t-test. *p<0.05, represent significance with respect to the indicated group.